Forest Laboratories is an American pharmaceutical company headquartered in New York City. The company's research and development spending has grown rapidly in recent years and, as of 2007, approached almost a billion U.S. dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.The company also has offices in St. Louis, Cincinnati, Jersey City, Oakland, Dublin, Kent and Paris. Wikipedia.
Forest Laboratories | Date: 2015-02-04
Oral dosage forms comprising donepezil or a pharmaceutically acceptable salt thereof (e.g., donepezil hydrochloride) alone or in combination with a second active ingredient (e.g., memantine hydrochloride or a pharmaceutically acceptable salt thereof) for the treatment of Alzheimers disease are provided. The oral dosage forms comprise donepezil granules that may be sprinkled on food and can significantly improve compliance in patients with swallowing difficulty.
Forest Laboratories | Date: 2015-01-29
The present invention is directed to stable chemical compositions and dosage forms that comprise nebivolol and valsartan and which achieve therapeutically effective plasma levels of both actives in hypertensive patients following administration, as well as to methods of lowering blood pressure and treating hypertension using such compositions and dosage forms.
Forest Laboratories | Date: 2016-07-20
The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
Forest Laboratories | Date: 2016-08-30
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
Forest Laboratories | Date: 2016-03-11
The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.
Forest Laboratories | Date: 2016-08-11
The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimers disease or neuropathic pain.
Ironwood Pharmaceuticals and Forest Laboratories | Date: 2016-03-31
The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.
Forest Laboratories | Date: 2016-02-10
Forest Laboratories | Date: 2015-03-04
The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration.
Ironwood Pharmaceuticals and Forest Laboratories | Date: 2015-01-15
Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (linaclotide; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.